A group of investors, including Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group, led a $111m Series A round in Zephyr AI, a healthcare technology company committed to developing fast and explainable AI solutions to democratize precision medicine. “The US has the highest rate of avoidable cancer and cardiometabolic-related deaths among any high-income country. We must do better. At Zephyr AI, we are harnessing the power of AI to extract novel insights to better define patient stratification and response predictions as well as improve federation of real-world data. With our world-class team, and the support of this investor group, we are deploying one of the largest clinicogenomic datasets that has unprecedented breadth across disease states and data partners. Collectively, we are now well positioned to support our mission of democratizing precision medicine, enhancing both the speed and success of clinical trials,” Grant Verstandig, Zephyr AI Co-Founder and Executive Chairman.